SARS-CoV-2 infection as a potential trigger of aplastic anemia in the context of clonal hematopoiesis

Background Aplastic anemia (AA) is a rare, immune-mediated bone marrow failure syndrome in which viral infections are recognized as established triggers; however, the role of SARS-CoV-2 infection and vaccination in its pathogenesis is not well understood. Methods In this retrospective single-center study, we assessed temporal trends in all patients diagnosed with AA between 2009 and 2025 and analyzed patients diagnosed between 2020 and 2023 in detail. Clinical characteristics, SARS-CoV-2 antibody profiles, serological autoimmune parameters, and cytokine signatures were assessed and compared according to infection and vaccination status. Stored serum samples from the routine diagnostic work-up, collected around diagnosis and before immunosuppressive treatment, were available for all patients diagnosed between 2020 and 2023. Results Of 65 patients, 36 were diagnosed before (2009–2019) and 29 during or after the pandemic (2020–2025). There was a non-significant increase in the annual numbers from 2020 onwards (median 4.5 vs. 3; p = 0.06) and a significantly higher median age at AA diagnosis (64 vs. 43 years; p = 0.01). Of the 18 patients from the early pandemic years (2020–2023), only two reported prior SARS-CoV-2 infection, but 67% exhibited anti-nucleocapsid antibodies, suggesting a high prevalence of unrecognized infections. Antibody kinetics indicated that most infections occurred close to AA onset. Serological autoimmune parameters were infrequent and not associated with infection or vaccination status. Irrespective of infection/vaccination status, cytokine profiling revealed a consistent inflammatory signature with markedly elevated TNFβ and IL-13. Three patients with serological evidence of infection showed pronounced activation of IL-1α, IL-6, and IL-10, marked lymphocytic bone marrow infiltration, and mutations associated with clonal hematopoiesis ( ASXL1 , DNMT3A , TET2 ). One of these patients relapsed after a SARS-CoV-2 reinfection. Conclusions In this single-center case series, most patients with AA diagnosed during the pandemic had serological evidence of a previous, often unrecognized SARS-CoV-2 infection, which in most cases occurred close to disease onset. Although this temporal association does not establish causality, it is compatible with SARS-CoV-2 acting as a trigger of AA in susceptible individuals. Vaccination was not associated with autoimmune phenomena. Whether clonal hematopoiesis contributes to disease susceptibility should be investigated in larger, multicenter cohorts.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-13
DOI
https://doi.org/10.3389/fimmu.2026.1991581
Primary Topic
Blood disorders and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

SARS-CoV-2 infection as a potential trigger of aplastic anemia in the context of clonal hematopoiesis

Antonio Vogelsberg, Falko Fend, Lennart Harland, Wichard Vogel et al.
Frontiers in Immunology
Blood disorders and treatments
article

SARS-CoV-2 infection as a potential trigger of aplastic anemia in the context of clonal hematopoiesis

Antonio Vogelsberg, Falko Fend, Lennart Harland, Wichard Vogel, Claudia Lengerke, Tamam Bakchoul, Friederike Schwartz, Günalp Uzun, Reinhild Klein
article en

Abstract

Background Aplastic anemia (AA) is a rare, immune-mediated bone marrow failure syndrome in which viral infections are recognized as established triggers; however, the role of SARS-CoV-2 infection and vaccination in its pathogenesis is not well understood. Methods In this retrospective single-center study, we assessed temporal trends in all patients diagnosed with AA between 2009 and 2025 and analyzed patients diagnosed between 2020 and 2023 in detail. Clinical characteristics, SARS-CoV-2 antibody profiles, serological autoimmune parameters, and cytokine signatures were assessed and compared according to infection and vaccination status. Stored serum samples from the routine diagnostic work-up, collected around diagnosis and before immunosuppressive treatment, were available for all patients diagnosed between 2020 and 2023. Results Of 65 patients, 36 were diagnosed before (2009–2019) and 29 during or after the pandemic (2020–2025). There was a non-significant increase in the annual numbers from 2020 onwards (median 4.5 vs. 3; p = 0.06) and a significantly higher median age at AA diagnosis (64 vs. 43 years; p = 0.01). Of the 18 patients from the early pandemic years (2020–2023), only two reported prior SARS-CoV-2 infection, but 67% exhibited anti-nucleocapsid antibodies, suggesting a high prevalence of unrecognized infections. Antibody kinetics indicated that most infections occurred close to AA onset. Serological autoimmune parameters were infrequent and not associated with infection or vaccination status. Irrespective of infection/vaccination status, cytokine profiling revealed a consistent inflammatory signature with markedly elevated TNFβ and IL-13. Three patients with serological evidence of infection showed pronounced activation of IL-1α, IL-6, and IL-10, marked lymphocytic bone marrow infiltration, and mutations associated with clonal hematopoiesis ( ASXL1 , DNMT3A , TET2 ). One of these patients relapsed after a SARS-CoV-2 reinfection. Conclusions In this single-center case series, most patients with AA diagnosed during the pandemic had serological evidence of a previous, often unrecognized SARS-CoV-2 infection, which in most cases occurred close to disease onset. Although this temporal association does not establish causality, it is compatible with SARS-CoV-2 acting as a trigger of AA in susceptible individuals. Vaccination was not associated with autoimmune phenomena. Whether clonal hematopoiesis contributes to disease susceptibility should be investigated in larger, multicenter cohorts.

Frontiers in ImmunologyVol. 17
Universitätsklinikum Tübingen (DE), University of Tübingen (DE)
Good health and well-being
Blood disorders and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon